BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either tra...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Improved survival with MEK inhibition in BRAF-mutated melanoma.
If you are the owner of this record, you can report an update to it here: Report update to this record